Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)

Our center plans to conduct a randomized, open-label, parallel-controlled, multi-center phase III study to evaluate the efficacy and safety of neoadjuvant chemotherapy combined with Toripalimab for HR+/HER2- breast cancer. The aim is to further explore the treatment strategy of chemotherapy with immunotherapy for patients with HR+/HER2- breast cancer, provide more treatment options for breast cancer patients, and offer a potential theoretical basis for the precision treatment of breast cancer.The primary study objective is to evaluate the pathologic complete response(PCR)and RCB0-1 ratio of ne

Trial Details

NCT ID
NCT06977893
Phase
PHASE3
Sponsor
First Affiliated Hospital of Zhejiang University
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • Neoadjuvant Chemotherapy in Combination with Toripalimab
  • Neoadjuvant Chemotherapy
Locations (sample)
  • Hangzhou, China|30.29365,120.16142
  • Hangzhou, China|30.29365,120.16142
  • Hangzhou, China|30.29365,120.16142
  • Harbin, China|45.75,126.65
  • Hefei, China|31.86389,117.28083

Key Eligibility Criteria

  • Female patients aged 18-75 years old;
  • ECOG score is 0-1 points;
  • breast cancer meets the following standards: Histologically confirmed invasive breast cancer with tumor diameter\>1cm (T1c-3; N0-3; M0). All pat…
  • Pathological examination of PD-L1 expression:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →